Celldex Therapeutics reported $61.32M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Celldex Therapeutics USD 61.32M 9.85M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Northwest Biotherapeutics USD 82.97M 4.93M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026